Page 342 - Glucose Monitoring Devices

References 349

[19] Cengiz E, Sherr JL, Weinzimer SA, Tamborlane WV. Clinical equipoise: an argument
for expedited approval of the first small step toward an autonomous artificial pancreas.
Expert Review of Medical Devices 2012;9(4):315e7.
[20] Garg S, Brazg RL, Bailey TS, Buckingham BA, Slover RH, Klonoff DC, et al. Reduc-
tion in duration of hypoglycemia by automatic suspension of insulin delivery: the in-
clinic ASPIRE study. Diabetes Technology and Therapeutics 2012;14(3):205e9.
[21] Agrawal P, Welsh JB, Kannard B, Askari S, Yang Q, Kaufman FR. Usage and effec-
tiveness of the low glucose suspend feature of the Medtronic Paradigm Veo insulin
pump. Journal of Diabetes Science and Technology 2011;5(5):1137e41.
[22] Bergenstal RM, Klonoff DC, Garg SK, Bode BW, Meredith M, Slover RH, et al.
Threshold-based insulin-pump interruption for reduction of hypoglycemia. New
England Journal of Medicine 2013;369(3):224e32.
[23] Ly TT, Nicholas JA, Retterath A, Lim EM, Davis EA, Jones TW. Effect of sensor-
augmented insulin pump therapy and automated insulin suspension vs standard insulin
pump therapy on hypoglycemia in patients with type 1 diabetes: a randomized clinical
trial. Journal of the American Medical Association 2013;310(12):1240e7.
[24] Agrawal P, Zhong A, Welsh JB, Shah R, Kaufman FR. Retrospective analysis of the
real-world use of the threshold suspend feature of sensor-augmented insulin pumps.
Diabetes Technology and Therapeutics 2015;17(5):316e9.
[25] Sherr JL, Palau Collazo M, Cengiz E, Michaud C, Carria L, Steffen AT, et al. Safety of
nighttime 2-hour suspension of Basal insulin in pump-treated type 1 diabetes even in
the absence of low glucose. Diabetes Care 2014;37(3):773e9.
[26] Danne T, Tsioli C, Kordonouri O, Blaesig S, Remus K, Roy A, et al. The PILGRIM
study: in silico modeling of a predictive low glucose management system and feasi-
bility in youth with type 1 diabetes during exercise. Diabetes Technology and Thera-
peutics 2014;16(6):338e47.
[27] Maahs DM, Calhoun P, Buckingham BA, Chase HP, Hramiak I, Lum J, et al.
A randomized trial of a home system to reduce nocturnal hypoglycemia in type 1
diabetes. Diabetes Care 2014;37(7):1885e91.
[28] Buckingham BA, Raghinaru D, Cameron F, Bequette BW, Chase HP, Maahs DM, et al.
Predictive low-glucose insulin suspension reduces duration of nocturnal hypoglycemia
in children without increasing ketosis. Diabetes Care 2015;38(7):1197e204.
[29] Calhoun PM, Buckingham BA, Maahs DM, Hramiak I, Wilson DM, Aye T, et al.
Efficacy of an overnight predictive low-glucose suspend system in relation to hypogly-
cemia risk factors in youth and adults with type 1 diabetes. Journal of Diabetes Science
and Technology 2016;10(6):1216e21.
[30] Buckingham BA, Bailey TS, Christiansen M, Garg S, Weinzimer S, Bode B, et al.
Evaluation of a predictive low-glucose management system in-clinic. Diabetes
Technology and Therapeutics 2017;19(5):288e92.
[31] Abraham MB, Nicholas JA, Smith GJ, Fairchild JM, King BR, Ambler GR, et al.
Reduction in hypoglycemia with the predictive low-glucose management system: a
long-term randomized controlled trial in adolescents with type 1 diabetes. Diabetes
Care 2018;41(2):303e10.
[32] Wood MA, Shulman DI, Forlenza GP, Bode BW, Pinhas-Hamiel O, Buckingham BA,
et al. In-clinic evaluation of the MiniMed 670G system “suspend before low” feature in
children with type 1 diabetes. Diabetes Technology and Therapeutics 2018;20(11):
731e7.